Patompon Wongtrakoongate
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Patompon Wongtrakoongate has a total of 183 co-authors. Here are the top co-authors by number of shared publications:
Suradej Hongeng
8 shared publications- Arunee Thitithanyanont
Mahidol University
7 shared publications Nut Phueakphud
Department of Biochemistry, Faculty of Science, Mahidol University, Bangkok 10400, Thailand; Center for Neuroscience, Faculty of Science, Mahidol University, Bangkok 10400, Thailand
6 shared publicationsSucheewin Krobthong
Center of Excellence in Natural Products Chemistry, Department of Chemistry, Faculty of Science, Chulalongkorn University, Bangkok, 10330, Thailand
5 shared publications- Suradej Hongeng
Division of Hematology and Oncology, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
5 shared publications Yodying Yingchutrakul
National Center for Genetic Engineering and Biotechnology, National Science and Technology Development Agency, Pathum Thani 12120, Thailand
4 shared publications
Latest Publications
- Open Access
- 10 August 2026
- Published by Elsevier in SSRN Electronic Journal
Circular RNA vaccines encoding Pvs25 induce antibodies that block Plasmodium vivax transmission
Plasmodium vivax is a major malaria parasite that causes acute illness in millions of people each year. Transmission-blocking vaccines (TBVs) could contribute substantially to malaria elimination, although none has yet been approved. We previously demonstrated that a nucleoside-modified mRNA–lipid nanoparticle (mRNA-LNP) vaccine targeting Pvs25, a leading P. vivax TBV antigen, elicited potent and durable transmission-blocking immunity in mice. Emerging evidence suggests that circular RNA (circRNA) may enhance RNA stability, prolong antigen expression, and potentially reduce manufacturing costs compared with conventional linear mRNA. We therefore developed and evaluated two circular Pvs25 RNA-LNP vaccines: one encoding wild-type Pvs25 and another encoding Pvs25 fused to the MHC class I trafficking domain (MITD). Their immunogenicity and functional activity were compared with those of a linear nucleoside-modified Pvs25 mRNA-LNP vaccine. In mice, a single immunization with either the circular or linear Pvs25 vaccine induced detectable Pvs25-specific antibodies, while booster immunization substantially increased antibody titers and resulted in complete inhibition of P. vivax development in mosquitoes. Both vaccines also elicited robust memory B-cell responses and cytokine-producing cellular responses. Together, these findings demonstrate the potential of circRNA as a platform for malaria vaccine development and support further evaluation in non-human primates.
- 10 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessCircular RNA vaccines encoding Pvs25 induce antibodies that block Plasmodium vivax transmission
Plasmodium vivax is a major malaria parasite that causes acute illness in millions of people each year. Transmission-blocking vaccines (TBVs) could contribute substantially to malaria elimination, although none has yet been approved. We previously demonstrated that a nucleoside-modified mRNA–lipid nanoparticle (mRNA-LNP) vaccine targeting Pvs25, a leading P. vivax TBV antigen, elicited potent and durable transmission-blocking immunity in mice. Emerging evidence suggests that circular RNA (circRNA) may enhance RNA stability, prolong antigen expression, and potentially reduce manufacturing costs compared with conventional linear mRNA. We therefore developed and evaluated two circular Pvs25 RNA-LNP vaccines: one encoding wild-type Pvs25 and another encoding Pvs25 fused to the MHC class I trafficking domain (MITD). Their immunogenicity and functional activity were compared with those of a linear nucleoside-modified Pvs25 mRNA-LNP vaccine. In mice, a single immunization with either the circular or linear Pvs25 vaccine induced detectable Pvs25-specific antibodies, while booster immunization substantially increased antibody titers and resulted in complete inhibition of P. vivax development in mosquitoes. Both vaccines also elicited robust memory B-cell responses and cytokine-producing cellular responses. Together, these findings demonstrate the potential of circRNA as a platform for malaria vaccine development and support further evaluation in non-human primates.
- 24 February 2025
- Published by Elsevier in Cytotherapy
- Vol. 27 (6) , 782-789
Efficient large-scale expansion of cord blood-derived NK cells: leveraging lipopolysaccharide for enhanced NK cell production
- 24 February 2025
- Published by Elsevier in Cytotherapy
- Vol. 27 (6) , 782-789
Efficient large-scale expansion of cord blood-derived NK cells: leveraging lipopolysaccharide for enhanced NK cell production
- 30 November 2024
- Published by Elsevier in Phytomedicine
- Vol. 136, 156279
Andrographolide attenuates SARS-CoV-2 infection via an up-regulation of glutamate-cysteine ligase catalytic subunit (GCLC)
- 30 November 2024
- Published by Elsevier in Phytomedicine
- Vol. 136, 156279
Andrographolide attenuates SARS-CoV-2 infection via an up-regulation of glutamate-cysteine ligase catalytic subunit (GCLC)
- 14 October 2024
- Published by Elsevier in Life Sciences
- Vol. 358, 123132
KHDRBS3 facilitates self-renewal and temozolomide resistance of glioblastoma cell lines
- 14 October 2024
- Published by Elsevier in Life Sciences
- Vol. 358, 123132
KHDRBS3 facilitates self-renewal and temozolomide resistance of glioblastoma cell lines
- Open Access
KHDRBS3 facilitates self-renewal and temozolomide resistance of glioblastoma cell lines
Glioblastoma is a deadly tumor which possesses glioblastoma stem cell populations involved in temozolomide resistance. To gain insight into the mechanisms of self-renewing and therapy-resistant cancer stem cells, subcellular proteomics was utilized to identify proteins whose expression is enriched in U251-derived glioblastoma stem-like cells. The RNA binding protein KHDRBS3 was successfully identified as a gene up-regulated in the cancer stem cell population compared with its differentiated derivatives. Depletion of KHDRBS3 by RNA silencing led to a decrease in cell proliferation, neurosphere formation, migration, and expression of genes involved in glioblastoma stemness. Importantly, temozolomide sensitivity can be induced by the gene knockdown. Collectively, our results highlight KHDRBS3 as a novel factor associated with self-renewal of glioblastoma stem-like cells and temozolomide resistance. As a consequence, targeting KHDRBS3 may help eradicate glioblastoma stem-like cells.
Open AccessKHDRBS3 facilitates self-renewal and temozolomide resistance of glioblastoma cell lines
Glioblastoma is a deadly tumor which possesses glioblastoma stem cell populations involved in temozolomide resistance. To gain insight into the mechanisms of self-renewing and therapy-resistant cancer stem cells, subcellular proteomics was utilized to identify proteins whose expression is enriched in U251-derived glioblastoma stem-like cells. The RNA binding protein KHDRBS3 was successfully identified as a gene up-regulated in the cancer stem cell population compared with its differentiated derivatives. Depletion of KHDRBS3 by RNA silencing led to a decrease in cell proliferation, neurosphere formation, migration, and expression of genes involved in glioblastoma stemness. Importantly, temozolomide sensitivity can be induced by the gene knockdown. Collectively, our results highlight KHDRBS3 as a novel factor associated with self-renewal of glioblastoma stem-like cells and temozolomide resistance. As a consequence, targeting KHDRBS3 may help eradicate glioblastoma stem-like cells.
- Open Access
A phage nucleus-associated protein from the jumbophage Churi inhibits bacterial growth through protein translation interference
Antibacterial proteins inhibiting Pseudomonas aeruginosa have been identified in various phages and explored as antibiotic alternatives. Here, we isolated a phiKZ-like phage, Churi, which encodes 364 open reading frames. We examined 15 early-expressed phage proteins for their ability to inhibit bacterial growth, and found that gp335, closely related to phiKZ-gp14, exhibits antibacterial activity. Similar to phiKZ-gp14, recently shown to form a complex with the P. aeruginosa ribosome, we predict experimentally that gp335 interacts with ribosomal proteins, suggesting its involvement in protein translation. GFP-tagged gp335 clusters around the phage nucleus as early as 15 minutes post-infection and remains associated with it throughout the infection, suggesting its role in protein expression in the cell cytoplasm. CRISPR-Cas13-mediated deletion of gp355 reveals that the mutant phage has a prolonged latent period. Altogether, we demonstrate that gp335 is an antibacterial protein of nucleus-forming phages that associates with the ribosomes at the phage nucleus.
Open AccessA phage nucleus-associated protein from the jumbophage Churi inhibits bacterial growth through protein translation interference
Antibacterial proteins inhibiting Pseudomonas aeruginosa have been identified in various phages and explored as antibiotic alternatives. Here, we isolated a phiKZ-like phage, Churi, which encodes 364 open reading frames. We examined 15 early-expressed phage proteins for their ability to inhibit bacterial growth, and found that gp335, closely related to phiKZ-gp14, exhibits antibacterial activity. Similar to phiKZ-gp14, recently shown to form a complex with the P. aeruginosa ribosome, we predict experimentally that gp335 interacts with ribosomal proteins, suggesting its involvement in protein translation. GFP-tagged gp335 clusters around the phage nucleus as early as 15 minutes post-infection and remains associated with it throughout the infection, suggesting its role in protein expression in the cell cytoplasm. CRISPR-Cas13-mediated deletion of gp355 reveals that the mutant phage has a prolonged latent period. Altogether, we demonstrate that gp335 is an antibacterial protein of nucleus-forming phages that associates with the ribosomes at the phage nucleus.
- Open Access
- 18 December 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-17
Upregulated LAMA3 modulates proliferation, adhesion, migration and epithelial‑to‑mesenchymal transition of cholangiocarcinoma cells
A poor outcome for cholangiocarcinoma (CCA) patients is still a clinical challenge. CCA is typically recognized by the desmoplastic nature, which accounts for its malignancy. Among various extracellular matrix proteins, laminin is the most potent inducer for CCA migration. Herein, we accessed the expression profiles of laminin gene family and explored the significance of the key laminin subunit on CCA aggressiveness. Of all 11 laminin genes, LAMA3, LAMA5, LAMB3 and LAMC2 were concordantly upregulated based on the analysis of multiple public transcriptomic datasets and also overexpressed in Thai CCA cell lines and patient tissues in which LAMA3A upregulated in the highest frequency (97%) of the cases. Differential expression genes (DEGs) analysis of low and high laminin signature groups revealed LAMA3 as the sole common DEG in all investigated datasets. Restratifying CCA samples according to LAMA3 expression indicated the association of LAMA3 in the focal adhesion pathway. Silencing LAMA3 revealed that it plays important roles in CCA cell proliferation, adhesion, migration and epithelial-to-mesenchymal transition. Taken together, this research signifies the roles of dysregulated ECM homeostasis in CCA malignancy and highlights, for the first time, the potential usage of LAMA3 as the diagnostic biomarker and the therapeutic target to tackle the CCA stromal.
- 18 December 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-17
Open AccessUpregulated LAMA3 modulates proliferation, adhesion, migration and epithelial‑to‑mesenchymal transition of cholangiocarcinoma cells
A poor outcome for cholangiocarcinoma (CCA) patients is still a clinical challenge. CCA is typically recognized by the desmoplastic nature, which accounts for its malignancy. Among various extracellular matrix proteins, laminin is the most potent inducer for CCA migration. Herein, we accessed the expression profiles of laminin gene family and explored the significance of the key laminin subunit on CCA aggressiveness. Of all 11 laminin genes, LAMA3, LAMA5, LAMB3 and LAMC2 were concordantly upregulated based on the analysis of multiple public transcriptomic datasets and also overexpressed in Thai CCA cell lines and patient tissues in which LAMA3A upregulated in the highest frequency (97%) of the cases. Differential expression genes (DEGs) analysis of low and high laminin signature groups revealed LAMA3 as the sole common DEG in all investigated datasets. Restratifying CCA samples according to LAMA3 expression indicated the association of LAMA3 in the focal adhesion pathway. Silencing LAMA3 revealed that it plays important roles in CCA cell proliferation, adhesion, migration and epithelial-to-mesenchymal transition. Taken together, this research signifies the roles of dysregulated ECM homeostasis in CCA malignancy and highlights, for the first time, the potential usage of LAMA3 as the diagnostic biomarker and the therapeutic target to tackle the CCA stromal.
- Open Access
Proteomics and Molecular Docking Analyses Reveal the Bio-Chemical and Molecular Mechanism Underlying the Hypolipidemic Activity of Nano-Liposomal Bioactive Peptides in 3T3-L1 Adipocytes
Obesity is a global health concern. Physical activities and eating nutrient-rich functional foods can prevent obesity. In this study, nano-liposomal encapsulated bioactive peptides (BPs) were developed to reduce cellular lipids. The peptide sequence NH2-PCGVPMLTVAEQAQ-CO2H was chemically synthesized. The limited membrane permeability of the BPs was improved by encapsulating the BPs with a nano-liposomal carrier, which was produced by thin-layer formation. The nano-liposomal BPs had a diameter of ~157 nm and were monodispersed in solution. The encapsulation capacity was 61.2 ± 3.2%. The nano-liposomal BPs had no significant cytotoxicity on the tested cells, keratinocytes, fibroblasts, and adipocytes. The in vitro hypolipidemic activity significantly promoted the breakdown of triglycerides (TGs). Lipid droplet staining was correlated with TG content. Proteomics analysis identified 2418 differentially expressed proteins. The nano-liposomal BPs affected various biochemical pathways beyond lipolysis. The nano-liposomal BP treatment decreased the fatty acid synthase expression by 17.41 ± 1.17%. HDOCK revealed that the BPs inhibited fatty acid synthase (FAS) at the thioesterase domain. The HDOCK score of the BPs was lower than that of orlistat, a known obesity drug, indicating stronger binding. Proteomics and molecular docking analyses confirmed that the nano-liposomal BPs were suitable for use in functional foods to prevent obesity.
Open AccessProteomics and Molecular Docking Analyses Reveal the Bio-Chemical and Molecular Mechanism Underlying the Hypolipidemic Activity of Nano-Liposomal Bioactive Peptides in 3T3-L1 Adipocytes
Obesity is a global health concern. Physical activities and eating nutrient-rich functional foods can prevent obesity. In this study, nano-liposomal encapsulated bioactive peptides (BPs) were developed to reduce cellular lipids. The peptide sequence NH2-PCGVPMLTVAEQAQ-CO2H was chemically synthesized. The limited membrane permeability of the BPs was improved by encapsulating the BPs with a nano-liposomal carrier, which was produced by thin-layer formation. The nano-liposomal BPs had a diameter of ~157 nm and were monodispersed in solution. The encapsulation capacity was 61.2 ± 3.2%. The nano-liposomal BPs had no significant cytotoxicity on the tested cells, keratinocytes, fibroblasts, and adipocytes. The in vitro hypolipidemic activity significantly promoted the breakdown of triglycerides (TGs). Lipid droplet staining was correlated with TG content. Proteomics analysis identified 2418 differentially expressed proteins. The nano-liposomal BPs affected various biochemical pathways beyond lipolysis. The nano-liposomal BP treatment decreased the fatty acid synthase expression by 17.41 ± 1.17%. HDOCK revealed that the BPs inhibited fatty acid synthase (FAS) at the thioesterase domain. The HDOCK score of the BPs was lower than that of orlistat, a known obesity drug, indicating stronger binding. Proteomics and molecular docking analyses confirmed that the nano-liposomal BPs were suitable for use in functional foods to prevent obesity.